Cost-minimization analysis of alternative treatment strategies for achalasia

Thomas Imperiale, J. Barry O'Connor, Michael F. Vaezi, Joel E. Richter

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

OBJECTIVE: The aim of this study is to compare the costs per cure of alternative strategies for the treatment of achalasia. METHODS: A cost-minimization model compared three strategies for otherwise healthy adults of any age with achalasia: 1) laparoscopic Heller myotomy with fundoplication (LHM); 2) pneumatic dilation (PD), with LHM reserved for treatment failures; 3) botulinum toxin (Botox) injection of the lower esophageal sphincter, with PD reserved for treatment failures. Probabilities of short- and long-term efficacy, treatment failure, symptomatic recurrence rates, and complications were derived from the published literature. Only direct costs were considered during the 5-yr time horizon. RESULTS: Respective reference case costs per cure of PD, Botox, and LHM strategies were $3,111, $3,723, and $10,792. Despite short- and long-term efficacy of 96% and 94%, respectively, the LHM strategy was most costly. Initial PD remained less costly than initial Botox, provided that rates of PD efficacy and perforation were ≥70% and <9.5%, respectively, and cost of a Botox session was ≥$450. The results were not sensitive to the probabilities of short- and long-term response to Botox, recurrence after PD, LHM efficacy, and post-LHM gastroesophageal reflux disease, nor to the costs of LHM and PD. CONCLUSIONS: For otherwise healthy patients with achalasia, initial PD is the least costly strategy provided that the PD perforation rate remains <10%. Initial Botox is less costly only when nonendoscopic-related costs decrease by 25%. Initial LHM is the most costly strategy under all clinically plausible scenarios. Subsequent analyses should include a longer time horizon and an assessment of patient preference for each strategy. (C) 2000 by Am. Coll. of Gastroenterology.

Original languageEnglish
Pages (from-to)2737-2745
Number of pages9
JournalAmerican Journal of Gastroenterology
Volume95
Issue number10
DOIs
StatePublished - 2000

Fingerprint

Esophageal Achalasia
Dilatation
Botulinum Toxins
Costs and Cost Analysis
Treatment Failure
Therapeutics
Recurrence
Fundoplication
Lower Esophageal Sphincter
Patient Preference
Gastroenterology
Gastroesophageal Reflux
Injections

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Cost-minimization analysis of alternative treatment strategies for achalasia. / Imperiale, Thomas; O'Connor, J. Barry; Vaezi, Michael F.; Richter, Joel E.

In: American Journal of Gastroenterology, Vol. 95, No. 10, 2000, p. 2737-2745.

Research output: Contribution to journalArticle

Imperiale, Thomas ; O'Connor, J. Barry ; Vaezi, Michael F. ; Richter, Joel E. / Cost-minimization analysis of alternative treatment strategies for achalasia. In: American Journal of Gastroenterology. 2000 ; Vol. 95, No. 10. pp. 2737-2745.
@article{3f716881a9e64e24b7b4829f1d1ac6c1,
title = "Cost-minimization analysis of alternative treatment strategies for achalasia",
abstract = "OBJECTIVE: The aim of this study is to compare the costs per cure of alternative strategies for the treatment of achalasia. METHODS: A cost-minimization model compared three strategies for otherwise healthy adults of any age with achalasia: 1) laparoscopic Heller myotomy with fundoplication (LHM); 2) pneumatic dilation (PD), with LHM reserved for treatment failures; 3) botulinum toxin (Botox) injection of the lower esophageal sphincter, with PD reserved for treatment failures. Probabilities of short- and long-term efficacy, treatment failure, symptomatic recurrence rates, and complications were derived from the published literature. Only direct costs were considered during the 5-yr time horizon. RESULTS: Respective reference case costs per cure of PD, Botox, and LHM strategies were $3,111, $3,723, and $10,792. Despite short- and long-term efficacy of 96{\%} and 94{\%}, respectively, the LHM strategy was most costly. Initial PD remained less costly than initial Botox, provided that rates of PD efficacy and perforation were ≥70{\%} and <9.5{\%}, respectively, and cost of a Botox session was ≥$450. The results were not sensitive to the probabilities of short- and long-term response to Botox, recurrence after PD, LHM efficacy, and post-LHM gastroesophageal reflux disease, nor to the costs of LHM and PD. CONCLUSIONS: For otherwise healthy patients with achalasia, initial PD is the least costly strategy provided that the PD perforation rate remains <10{\%}. Initial Botox is less costly only when nonendoscopic-related costs decrease by 25{\%}. Initial LHM is the most costly strategy under all clinically plausible scenarios. Subsequent analyses should include a longer time horizon and an assessment of patient preference for each strategy. (C) 2000 by Am. Coll. of Gastroenterology.",
author = "Thomas Imperiale and O'Connor, {J. Barry} and Vaezi, {Michael F.} and Richter, {Joel E.}",
year = "2000",
doi = "10.1016/S0002-9270(00)01974-2",
language = "English",
volume = "95",
pages = "2737--2745",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Cost-minimization analysis of alternative treatment strategies for achalasia

AU - Imperiale, Thomas

AU - O'Connor, J. Barry

AU - Vaezi, Michael F.

AU - Richter, Joel E.

PY - 2000

Y1 - 2000

N2 - OBJECTIVE: The aim of this study is to compare the costs per cure of alternative strategies for the treatment of achalasia. METHODS: A cost-minimization model compared three strategies for otherwise healthy adults of any age with achalasia: 1) laparoscopic Heller myotomy with fundoplication (LHM); 2) pneumatic dilation (PD), with LHM reserved for treatment failures; 3) botulinum toxin (Botox) injection of the lower esophageal sphincter, with PD reserved for treatment failures. Probabilities of short- and long-term efficacy, treatment failure, symptomatic recurrence rates, and complications were derived from the published literature. Only direct costs were considered during the 5-yr time horizon. RESULTS: Respective reference case costs per cure of PD, Botox, and LHM strategies were $3,111, $3,723, and $10,792. Despite short- and long-term efficacy of 96% and 94%, respectively, the LHM strategy was most costly. Initial PD remained less costly than initial Botox, provided that rates of PD efficacy and perforation were ≥70% and <9.5%, respectively, and cost of a Botox session was ≥$450. The results were not sensitive to the probabilities of short- and long-term response to Botox, recurrence after PD, LHM efficacy, and post-LHM gastroesophageal reflux disease, nor to the costs of LHM and PD. CONCLUSIONS: For otherwise healthy patients with achalasia, initial PD is the least costly strategy provided that the PD perforation rate remains <10%. Initial Botox is less costly only when nonendoscopic-related costs decrease by 25%. Initial LHM is the most costly strategy under all clinically plausible scenarios. Subsequent analyses should include a longer time horizon and an assessment of patient preference for each strategy. (C) 2000 by Am. Coll. of Gastroenterology.

AB - OBJECTIVE: The aim of this study is to compare the costs per cure of alternative strategies for the treatment of achalasia. METHODS: A cost-minimization model compared three strategies for otherwise healthy adults of any age with achalasia: 1) laparoscopic Heller myotomy with fundoplication (LHM); 2) pneumatic dilation (PD), with LHM reserved for treatment failures; 3) botulinum toxin (Botox) injection of the lower esophageal sphincter, with PD reserved for treatment failures. Probabilities of short- and long-term efficacy, treatment failure, symptomatic recurrence rates, and complications were derived from the published literature. Only direct costs were considered during the 5-yr time horizon. RESULTS: Respective reference case costs per cure of PD, Botox, and LHM strategies were $3,111, $3,723, and $10,792. Despite short- and long-term efficacy of 96% and 94%, respectively, the LHM strategy was most costly. Initial PD remained less costly than initial Botox, provided that rates of PD efficacy and perforation were ≥70% and <9.5%, respectively, and cost of a Botox session was ≥$450. The results were not sensitive to the probabilities of short- and long-term response to Botox, recurrence after PD, LHM efficacy, and post-LHM gastroesophageal reflux disease, nor to the costs of LHM and PD. CONCLUSIONS: For otherwise healthy patients with achalasia, initial PD is the least costly strategy provided that the PD perforation rate remains <10%. Initial Botox is less costly only when nonendoscopic-related costs decrease by 25%. Initial LHM is the most costly strategy under all clinically plausible scenarios. Subsequent analyses should include a longer time horizon and an assessment of patient preference for each strategy. (C) 2000 by Am. Coll. of Gastroenterology.

UR - http://www.scopus.com/inward/record.url?scp=0033791714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033791714&partnerID=8YFLogxK

U2 - 10.1016/S0002-9270(00)01974-2

DO - 10.1016/S0002-9270(00)01974-2

M3 - Article

C2 - 11051342

AN - SCOPUS:0033791714

VL - 95

SP - 2737

EP - 2745

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 10

ER -